Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Neuren Pharmaceuticals and Metabolic Pharmaceuticals have agreed to collaborate to co-develop a class of nerve repair compounds for the treatment of degenerative conditions such as peripheral neuropathy, motor neuron disease and repairing the brain or nerves after injuries.
Subscribe to our email newsletter
Neuren Pharmaceuticals and Metabolic Pharmaceuticals will jointly develop Neuren’s class of neuro-regenerative peptides (NRPs) with all intellectual property and commercial outcomes to be equally shared.
Furthermore, the two companies have announced that the joint collaboration has been awarded NZ$635,000 in grant funding from the Australia New Zealand Biotechnology Partnership Fund, which is part of the New Zealand Government’s Growth and Innovation Framework, designed to assist and speed collaboration between New Zealand and Australian biotech companies. The grant will meet 25% of the eligible project costs with Neuren contributing 25% and Metabolic 50%.
“This is significant for Neuren as it reduces our costs considerably and accelerates one of our new classes of drug candidates towards the clinic, while enabling Neuren to continue our focus on the clinical development of our neuroprotective compounds Glypromate and NNZ2566,” said Neuren’s CEO, David Clarke. “I am delighted to be entering this agreement with Metabolic.”